Cencora

Cencora

Global pharmaceutical distribution and services provider

Controls Technician 3

Full-TimeUpdated on 9/30/2026
$76.2k - $119.5k/yr

+ $2,500 sign-on bonus

Mid
Bachelor's
Romeoville, IL, USA
In Person

About the job

Requirements
  • A bachelor's degree in Electrical Engineering, Mechanical Engineering, or Facilities /Plant Management is preferred; technical vocational training or an equivalent combination of experience and education is required.
  • Normally requires four years of related and progressively responsible experience; a strong electrical background is preferred.
  • Strong technical and operational knowledge of mechanical, electrical, and electronic equipment and systems, with an aptitude for repair and maintenance activities.
  • Ability to read and interpret computer-aided design layouts, illustrated parts breakdown diagrams, and electrical circuitry diagrams and drawings.
  • Ability to diagnose and repair electrical and mechanical issues, including single-phase and three-phase electrical systems up to 600 volts, AC and DC motors, power supplies, frequency drives, servo drives, transformers, motor starters, proximity sensors, encoders, photo eyes, programmable logic controllers, human-machine interfaces, and PLC inputs and outputs.
  • Ability to create custom drawings, schematics, designs, cost estimates, and project management deliverables.
  • Ability to test equipment and instrumentation systems, including electrical, pneumatic, hydraulic, refrigeration, and water treatment chemical systems.
  • Ability to read electrical schematics, wiring diagrams, and PLC ladder and block logic; load programs or configure PLCs, HMIs, and scanners.
  • Ability to program basic changes to PLC controllers, including modifying timing, adding alarms and logic for inputs or outputs, and wiring additional devices to PLCs and other controllers.
  • Ability to design, assemble, program, and diagnose materials handling equipment controls systems, including PLCs, remote I/O modules, digital and analog inputs and outputs, high-speed counters, encoders, proximity sensors, frequency drives, and servos.
  • Ability to diagnose, operate, and repair facility and materials handling equipment systems within the distribution center.
  • Working knowledge of computer systems and personal computers, including installation and setup of hard drives, RAM, network cards, monitor cards, and motherboards.
  • Computer software experience with Microsoft Office, including Excel, Word, and instant messaging, and materials handling equipment software such as RSLogix, Sort Director, GSMi, IPoint, and Flex Sort.
  • Ability to diagnose electrical control issues to the component level, including capacitors, inductors, diodes, LEDs, transistors, pressure transducers, flow meters, photovoltaic sensors, bridge rectifiers, and full-wave rectifiers.
  • Ability to troubleshoot device communication issues across materials handling equipment networks and other networks such as PROFIBUS, BACnet, LonWorks, PROFINET, CAN bus, and AS-i, including device IP addressing and network switches.
  • Ability to operate and diagnose chilled-water plant systems, including chillers, cooling towers, boilers, pumps, building automation systems, HVAC, and water treatment.
  • Strong analytical skills and ability to identify facilities-related maintenance problems and implement standard actions to resolve them within established timeframes and requirements.
  • Ability to communicate effectively orally and in writing.
  • Strong interpersonal skills.
  • Strong organizational skills and attention to detail.
  • Willingness to work extended hours as needed to meet productivity goals.
Responsibilities
  • Support the effective use and functionality of automated equipment within a fully automated distribution center.
  • Design, operate, assemble, repair, program, and diagnose materials handling equipment controls systems.
  • Create complete controls systems for small- to medium-sized automated materials handling equipment systems, including PLC controllers, remote I/O modules, and digital and analog inputs and outputs.
  • Create or design equipment using high-speed counters, encoders, proximity sensors, frequency drives, and servos.
  • Ensure effective preventive maintenance plans and schedules for facility equipment and systems.
  • Diagnose materials handling equipment and automated picking system errors and repair them appropriately.
  • Oversee maintenance, modifications, and system upgrades for materials handling equipment and automated picking system controls.
  • Assess the efficiency of materials handling equipment and automated picking systems and define necessary modifications.
  • Perform routine preventive maintenance tasks to support warehouse operations.
  • Maintain the computerized maintenance management system and enterprise asset management system for repairs required and performed on distribution center equipment.
  • Manage the inventory of spare parts.
  • Fulfill assigned compliance-critical responsibilities and ensure continual compliance with division, corporate, and regulatory requirements.
  • Perform related duties as assigned.
Desired Qualifications
  • Strong electrical background.
  • Knowledge of programmable logic controllers.

About the company

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Conshohocken, Pennsylvania

Founded

1907

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fiscal 2026 Q3 revenue reached $84.8 billion, and EPS guidance rose to $17.75-$17.95.
  • Cencora completed OneOncology in February 2026, strengthening specialty-pharmacy and oncology economics.
  • A $7 billion revolver and $1 billion buyback show lenders and management backing execution.

What critics are saying

  • Opioid litigation still carries a $4.2 billion accrued liability through 2039.
  • Maryland courts vacated Baltimore's $152 million verdict, but appeals can revive distributor exposure.
  • ASP rule changes and 340B guidance threaten community-oncology margins by 2028, hitting OneOncology.

What makes Cencora unique

  • Cencora pairs drug distribution with OneOncology, deepening specialty-care workflow integration.
  • Its global network spans U.S. Healthcare Solutions and International Healthcare Solutions across 51,000 employees.
  • Nucleus inventory tools and cell-gene therapy enablement embed Cencora inside provider operations.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Company News

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.

MarketScreener
Aug 5th, 2026
Cencora boosts credit facility to $7B, extends maturity to 2031

Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.

Yahoo Finance
Aug 1st, 2026
Cencora Q3 earnings preview: analysts expect $4.37 EPS on $84.89B revenue

Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.